and for those infected with the human immunodeficiency virus (HIV
) whose anemia is caused by the HIV
drug AZT (zidovudine). ESAs are also approved to reduce the number of transfusions during and after major surgery.
On Nov. 30, Amgen, manufacturer of the three ESAs – Aranesp [darbepoetin], Epogen, and Procrit -- provided FDA with information from the 733-patient PREPARE study of women who received chemotherapy before undergoing surgery for breast cancer.